Background: Chronic Hepatitis C is a public health problems in Pakistan, with 4.5% population infected. It is amenable to antiviral treatment. The ojective of this study was to determine the effect of antiviral treatment on leukocytes count during the treatment of hepatitis C.
Methods: In this descriptive case series sixty PCR positive Hepatitis C patients were included and were given standard interferon and ribavirin for a period of six months with a monthly follow up. Total leukocytes were measured at monthly interval to study change in their counts.
Results: The mean of baseline leukocytes was compared with the average mean leukocytes of six months treatment, and a decrease of 1603.36/mm3 was observed (p=0.000).
Conclusion: Six months treatment of chronic hepatitis C with standard interferon and ribavirin decreases leukocytes count to a significant level.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Unraveling the immunomodulatory and metabolic effects of bioactive glass S53P4 on macrophages in vitro.
J Mater Sci Mater Med
January 2025
Institute of Biomedicine, Faculty of Medicine, University of Turku, Turku, Finland.
Macrophage metabolism is closely linked to their phenotype and function, which is why there is growing interest in studying the metabolic reprogramming of macrophages. Bioactive glass (BG) S53P4 is a bioactive material used especially in bone applications. Additionally, BG S53P4 has been shown to affect macrophages, but the mechanisms through which the possible immunomodulatory effects are conveyed remain unclear.
View Article and Find Full Text PDFAssociation of increased serum I-309 with phenotypes, disease activity, and cytokine pattern in primary Sjögren's syndrome.
Clin Rheumatol
January 2025
Department of Laboratory Medicine, Huangyan Hospital of Wenzhou Medical University, Taizhou First People's Hospital, Taizhou, Zhejiang, China.
The aim of this study was to determine serum I-309 levels in primary Sjögren's syndrome (pSS) patients, as well as the association with disease phenotype, systemic activity, and T helper cell-related cytokines. A total of 58 pSS patients and 30 healthy controls (HC) were enrolled in this study. The concentrations of serum I-309, interleukin-4 (IL-4), IL-6, IL-9, IL-13, IL-17, IL-22, IL-23, tumor-necrosis factor-α (TNF-α), interferon-γ (IFN-γ), IFN-α, and IFN-β were measured with multiplex immunoassay.
View Article and Find Full Text PDFTDP43 augments astrocyte inflammatory activity through mtDNA-cGAS-STING axis in NMOSD.
J Neuroinflammation
January 2025
Department of Neurology, Center for Medical Research on Innovation and Translation, Institute of Clinical Medicine, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, China.
Abnormality in transactivating response region DNA binding protein 43 (TDP43) is well-recognized as the pathological hallmark of neurodegenerative diseases. However, the role of TDP43 in neuromyelitis optica spectrum disorder (NMOSD) remains unknown. Here, our observations demonstrate an upregulation of TDP43 in both in vitro and in vivo models of NMOSD, as well as in biological samples from NMOSD patients.
View Article and Find Full Text PDFEfficacy and safety of pharmacological treatments in inclusion body myositis: a systematic review.
RMD Open
January 2025
Department of Neuromuscular Diseases, University College London, London, UK
Objective: To identify the best evidence on the efficacy of treatment interventions for inclusion body myositis (IBM) and to describe their safety.
Methods: Systematic review of randomised controlled trials (RCTs) of pharmacological treatments of adults with IBM, conducted according to the Cochrane Handbook, updating a previous Cochrane review. The search strategy was run on Cochrane Neuromuscular Disease Group Specialized Register, CENTRAL, MEDLINE and EMBASE, ClinicalTrials.
Performance evaluation of the LIOFeron®TB/LTBI IGRA for screening of paediatric LTBI and tuberculosis.
Eur J Pediatr
January 2025
Infectious Diseases Unit, Department of Health Sciences, Anna Meyer Children's University Hospital, University of Florence, Florence, Italy.
Purpose: High-accuracy diagnostic screening tests for Mycobacterium tuberculosis (MTB) infection are required, primarily to detect patients with latent infections (LTBIs) in order to avoid their progression to active tuberculosis disease. The performance of the novel IGRA LIOFeron®TB/LTBI was evaluated in children. The originality of this test is the new MTB antigen contained (L-alanine dehydrogenase), identified as a tool to differentiate active TB from LTBI infection.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!